Intangibles

12 Months Ended

Jun. 30, 2021

Note 12. Intangibles

Non-current

assets


	Consolidated
	2021			2020
	A$’000			A$’000

Licensing agreement - at acquired fair value		16,408			16,408
Less: Accumulated amortisation		(5,082	)		(3,998	)

		11,326			12,410

Licensing agreement - at cost		10,858			—
Less: Accumulated amortisation		(181	)		—

		10,677			12,410

		22,003			12,410

Reconciliations

Reconciliations of the written down values at the beginning and end of the current and previous financial year are set out below:


	EVT801 licensing agreement A$’000			Paxalisib licensing agreement A$’000			Total A$’000

Balance at 1 July 2019		—			13,494			13,494
Additions
Disposals
Amortisation expense		—			(1,084	)		(1,084	)

Balance at 30 June 2020		—			12,410			12,410


Additions		10,858						10,858
Amortisation expense		(181	)		(1,084	)		(1,265	)

Balance at 30 June 2021		10,677			11,326			22,003

During the financial year the consolidated entity acquired exclusive rights to EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3).